摘要
目的:观察厄贝沙坦在老年肥胖高血压患者中的疗效。方法:入选老年肥胖高血压患者26例,予厄贝沙坦降压治疗,观察厄贝沙坦对血糖、血胰岛素、血脂联素、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、TC、TG及24h血压监测及脉搏波速率(PWV)的影响。结果:与治疗前相比,经厄贝沙坦治疗24周后,患者除血压降低外,胰岛素敏感指数升高[(-4.54±0.07)∶(-4.01±0.09)],P<0.05;血脂联素水平升高[(6.57±0.64)∶(8.27±0.81)mg/L],P<0.05;IL-6和PWV水平下降[(2.09±0.37)∶(1.36±0.25)ng/L,(1 754±64)∶(1 532±81)m/s],均P<0.001。相关分析显示,厄贝沙坦治疗前后PWV变化与收缩压、舒张压下降呈明显相关,而胰岛素敏感指数、血脂联素和IL-6的变化与其降压作用无相关性。结论:厄贝沙坦对老年肥胖高血压患者,具备独立于降压作用以外的改善胰岛素抵抗、减轻炎症反应的作用。
Objective：To explore the application of Irbesarta in elderly obesity patients with hypertension.Method：Twenty-six cases of elderly obesity patients with hypertension were selected.Irbesarta was administrated.The serum level of glucose,insulin,adiponectin,interlukin 6（IL-6）,high sensitivity C-reactive protein（hs-CRP）,total cholesterol（TC） and triglyceride（TG） were detected.Ambulatory blood pressure（ABP） and pulse wave velocity（PWV） were also monitored.Result：Twenty-four weeks post Irbesarta treatment,insulin sensitivity index（ISI） increased from（-4.54±0.07） to（-4.01±0.09）（P0.05）.The serum adiponectin increased from（6.57±0.64）mg/L to（8.27±0.81）mg/L（P0.05）.The serum IL-6 decreased from（2.09±0.37）ng/L to（1.36±0.25）ng/L（P0.001）.The level of PWV decreased from（1 754±64）m/s to（1 532±81） m/s（P0.001）.The change of PWV related to the decrese of systolic and diastolic blood pressure.Howerver,the change of the serum insulin sensitivity index,adiponectin and IL-6 did not relate to the decrease of blood pressure.Conclusion：Irbesarta can improve insulin resistance and alleviate inflamation independent of its role of decreasing blood pressure in elderly obesity patients with hypertension.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2011年第11期841-843,共3页
Journal of Clinical Cardiology
关键词
高血压
老年
代谢综合征
hypertention
elderly
metabolicsyndrome
